Complete remission of two canine cases with precursor-targeted immune-mediated anemia after combination therapy with prednisolone, cyclosporine, and oclacitinib
Background: Precursor-targeted immune-mediated anemia (PIMA) has been described in dogs presenting with nonregenerative anemia and evidence of ineffective erythropoiesis. Although it has been suggested that its occurrence may be related to the immune targeting of erythroid precursors, this pathogenesis has not been established. PIMA is mainly treated with glucocorticoids, and in cases where glucocorticoids alone are not effective, immunosuppressants are also used as combination therapy. However, not all cases of PIMA go into remission after these treatments.
Case Description: Two dogs with severe nonregenerative anemia diagnosed as PIMA based on the results of clinical pathological examinations, including bone marrow examination, were treated with whole-blood transfusion and immunosuppressive doses of prednisolone, mycophenolate mofetil, and cyclosporine. However, these treatments failed to achieve remission of PIMA. Therefore, concomitant administration of oclacitinib, which is a Janus kinase-1 inhibitor that has been applied recently to the treatment of immune-mediated diseases, was performed; this combined regimen improved the anemia and achieved complete remission of PIMA.
Conclusion: Oclacitinib may be an option for the treatment of PIMA in dogs failing to achieve remission with conventional immunosuppressive therapy.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Open veterinary journal - 13(2023), 9 vom: 04. Sept., Seite 1205-1211 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Yuki, Masashi [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1C4QK22F9J |
|---|
| Anmerkungen: |
Date Completed 23.10.2023 Date Revised 26.10.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5455/OVJ.2023.v13.i9.16 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM363349316 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM363349316 | ||
| 003 | DE-627 | ||
| 005 | 20231226093146.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5455/OVJ.2023.v13.i9.16 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1211.xml |
| 035 | |a (DE-627)NLM363349316 | ||
| 035 | |a (NLM)37842117 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Yuki, Masashi |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Complete remission of two canine cases with precursor-targeted immune-mediated anemia after combination therapy with prednisolone, cyclosporine, and oclacitinib |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 23.10.2023 | ||
| 500 | |a Date Revised 26.10.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background: Precursor-targeted immune-mediated anemia (PIMA) has been described in dogs presenting with nonregenerative anemia and evidence of ineffective erythropoiesis. Although it has been suggested that its occurrence may be related to the immune targeting of erythroid precursors, this pathogenesis has not been established. PIMA is mainly treated with glucocorticoids, and in cases where glucocorticoids alone are not effective, immunosuppressants are also used as combination therapy. However, not all cases of PIMA go into remission after these treatments | ||
| 520 | |a Case Description: Two dogs with severe nonregenerative anemia diagnosed as PIMA based on the results of clinical pathological examinations, including bone marrow examination, were treated with whole-blood transfusion and immunosuppressive doses of prednisolone, mycophenolate mofetil, and cyclosporine. However, these treatments failed to achieve remission of PIMA. Therefore, concomitant administration of oclacitinib, which is a Janus kinase-1 inhibitor that has been applied recently to the treatment of immune-mediated diseases, was performed; this combined regimen improved the anemia and achieved complete remission of PIMA | ||
| 520 | |a Conclusion: Oclacitinib may be an option for the treatment of PIMA in dogs failing to achieve remission with conventional immunosuppressive therapy | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Cyclosporine | |
| 650 | 4 | |a Dog | |
| 650 | 4 | |a Oclacitinib | |
| 650 | 4 | |a Precursor-targeted immune-mediated anemia | |
| 650 | 4 | |a Prednisolone | |
| 650 | 7 | |a Cyclosporine |2 NLM | |
| 650 | 7 | |a 83HN0GTJ6D |2 NLM | |
| 650 | 7 | |a Prednisolone |2 NLM | |
| 650 | 7 | |a 9PHQ9Y1OLM |2 NLM | |
| 650 | 7 | |a oclacitinib |2 NLM | |
| 650 | 7 | |a 99GS5XTB51 |2 NLM | |
| 650 | 7 | |a Potassium Iodide |2 NLM | |
| 650 | 7 | |a 1C4QK22F9J |2 NLM | |
| 650 | 7 | |a Immunosuppressive Agents |2 NLM | |
| 700 | 1 | |a Taira, Hiroto |e verfasserin |4 aut | |
| 700 | 1 | |a Narita, Momoko |e verfasserin |4 aut | |
| 700 | 1 | |a Inden, Takanori |e verfasserin |4 aut | |
| 700 | 1 | |a Yokota, Shunya |e verfasserin |4 aut | |
| 700 | 1 | |a Naito, Eiji |e verfasserin |4 aut | |
| 700 | 1 | |a Maeda, Sadatoshi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Open veterinary journal |d 2011 |g 13(2023), 9 vom: 04. Sept., Seite 1205-1211 |w (DE-627)NLM255157398 |x 2218-6050 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2023 |g number:9 |g day:04 |g month:09 |g pages:1205-1211 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5455/OVJ.2023.v13.i9.16 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2023 |e 9 |b 04 |c 09 |h 1205-1211 | ||